Találati lista | Tudóstér

001-es BibID:	BIBFORM054863
Első szerző:	Mezey Géza (idegsebész)
Cím:	Prognosis in human glioblastoma based on expression of ligand growth hormone-releasing hormone, pituitary-type growth hormone-releasing hormone receptor, its splicing variant receptors, EGF receptor and PTEN genes / Géza Mezey, Andrea Treszl, Andrew V. Schally, Normann L. Block, Laura Vízkeleti, Alíz Juhász, Álmos Klekner, János Nagy, Margit Balázs, Gábor Halmos, László Bognár
Dátum:	2014
ISSN:	0171-5216
Tárgyszavak:	Orvostudományok Egészségtudományok idegen nyelvű folyóiratközlemény külföldi lapban GHRH pGHRHR Splice variants SV1 EGFR PTEN? Human glioblastoma
Megjelenés:	Journal of Cancer Research and Clinical Oncology. - 140 : 10 (2014), p. 1641-1649. -
További szerzők:	Treszl Andrea (1974-) (molekuláris biológus) Schally, Andrew Victor Block, Norman L. Vízkeleti Laura (1984-) (molekuláris biológus, genetikus) Juhász Alíz (1977-) (molekuláris biológus) Klekner Álmos (1970-) (idegsebész) Nagy János (1956-) (matematikus) Balázs Margit (1952-) (sejtbiológus, molekuláris genetikus) Halmos Gábor (1962-) (gyógyszerész, receptorfarmakológus, experimentális onkológus) Bognár László (1958-) (idegsebész, gyermekidegsebész)
Pályázati támogatás:	TÁMOP-4.2.2.A-11/1/KONV-2012-0031 TÁMOP TÁMOP-4.2.2.A-11/1/KONV-2012-0025 (G.H.) TÁMOP
Internet cím:	Szerző által megadott URL DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon:

001-es BibID:	BIBFORM033893
035-os BibID:	PMID:8045917
Első szerző:	Qin, Yunfeng
Cím:	Bombesin antagonists inhibit in vitro and in vivo growth of human gastric cancer and binding of bombesin to its receptors / Yunfeng Qin, Gabor Halmos, Ren-Zhi Cai, Balazs Szoke, Tibor Ertl, Andrew V. Schally
Dátum:	1994
ISSN:	0171-5216
Megjegyzések:	We investigated the effect of bombesin/gastrin-releasing peptide (GRP) antagonist RC-3095 and other analogs on the growth of Hs746T human gastric cancer cells implanted in nude mice or cultured in vitro and on the binding of bombesin to its receptors. Nude mice bearing xenografts of the Hs746T cell line received s.c. injections of RC-3095 (10 micrograms twice daily) or the vehicle (control) for 21 days. Administration of antagonist RC-3095 inhibited the growth of Hs746T tumors. Treatment with RC-3095 produced a significant decrease in tumor volume, prolonged the tumor volume doubling time from 3.6 days to 5.1 days, and decreased the tumor growth rate by 76.9%. The tumor growth delay time in mice treated with RC-3095 was 2.8 days. Treatment with RC-3095 also decreased the final tumor weight by 88.3% and reduced DNA and protein contents in tumors by 91.5% and 89.5%, respectively, as compared to controls. The presence of specific receptors for bombesin/GRP was investigated on the crude membranes of implanted tumors of Hs746T cells. Saturation binding assays showed that the binding of [125I-Tyr4]bombesin to the membranes was saturable and reversible. Scatchard analysis indicated the presence of a single class of binding sites with a high affinity (Kd = 0.24 +/- 0.07 nM) and a low binding capacity (Bmax = 57.0 +/- 0.9 fmol/mg protein). In displacement studies, the binding of [125I-Tyr4]bombesin was inhibited in a dose-dependent manner by unlabelled bombesin(1-14), [Tyr4]-bombesin and GRP (14-27), but not by structurally unrelated peptides. Synthetic bombesin/GRP antagonists RC-3095, RC-3110, and RC-3950-II were all able to inhibit effectively the binding of [125I-Tyr4]bombesin to the membranes of Hs746T cells. RC-3950-II showed a higher binding affinity for bombesin receptors than RC-3095 or RC-3110. Addition of the non-hydrolyzable guanine-nucleotide analog GTP [S] to the binding buffer caused a significant reduction in the amount of [125I-Tyr4]bombesin bound to the cells, indicating that the bombesin receptor is coupled to a G-protein. In cell cultures, bombesin significantly stimulated the growth of Hs746T cells in vitro as shown by an increase in the uptake of [3H]thymidine. Bombesin antagonist RC-3095 could effectively inhibit the bombesin-stimulated growth of Hs746T cells in cultures. These observations suggest that bombesin/GRP may act as growth factors through specific receptors present on the membranes of Hs746T cells. Bombesin/GRP antagonists appear to nullify the effects of bombesin/GRP and may be useful for the treatment of gastric cancers.
Tárgyszavak:	Orvostudományok Gyógyszerészeti tudományok idegen nyelvű folyóiratközlemény külföldi lapban külföldön készült közlemény
Megjelenés:	Journal of Cancer Research And Clinical Oncology. - 120 : 9 (1994), p. 519-528. -
További szerzők:	Halmos Gábor (1962-) (gyógyszerész, receptorfarmakológus, experimentális onkológus) Cai, Ren-Zhi Szőke Balázs Ertl Tibor Schally, Andrew Victor
Internet cím:	Szerző által megadott URL DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon:

001-es BibID:	BIBFORM033663
035-os BibID:	PMID:10480336 WOS:000082305800002
Első szerző:	Szepesházi Károly
Cím:	Growth inhibition of experimental pancreatic cancers and sustained reduction in epidermal growth factor receptors during therapy with hormonal peptide analogs / Karoly Szepesházi, Gabor Halmos, Andrew V. Schally, José M. Arencibia, Kate Groot, Manuel Vadillo-Buenfil, Eulalia Rodriguez-Martin
Dátum:	1999
ISSN:	0171-5216
Megjegyzések:	Reduction in receptors for epidermal growth factor (EGF) in cancers appears to be one of the principal mechanisms through which peptide hormone analogs can inhibit tumor growth. In this study, hamsters with nitrosamine-induced pancreatic cancers were treated for 8 weeks with bombesin/gastrin-releasing peptide (GRP) antagonist RC-3095, somatostatin analog RC-160 or the luteinizing hormone-releasing hormone antagonist Cetrorelix, using sustained delivery systems releasing 20, 35 and 20 microg analog/ day respectively. To establish the pattern of changes in the number and affinity of EGF receptors on tumors, groups of animals were sacrificed at regular intervals during therapy. Chronic treatment with RC-3095 or Cetrorelix resulted in an early (day 10) and sustained reduction (71% or 69% respectively) in EGF receptors on pancreatic tumors. In contrast, RC-160 decreased receptor concentration by 60% only after 20 days. Among the histological characteristics of proliferation, the decrease in argyrophilic nucleolar organizer regions, but not apoptotic and mitotic indices, showed a correlation with the fall in EGF receptors. The concentration of the receptors returned to the control level 4 days after cessation of chronic treatment with RC-3095. The effect of single injections of RC-3095, RC-160 and Cetrorelix on EGF receptors was also investigated. RC-160 decreased the number of EGF receptors on pancreatic cancers by 31% 3 h after administration, but the receptors had returned to normal level at 6 h. RC-3095 and Cetrorelix caused a 67% and 59% decline, respectively, in EGF receptors only 6 h after injection and the concentration of receptors remained low for 24 h. Thus, the pattern of downregulation of EGF receptors in pancreatic cancers appears to depend on the peptide used for therapy. Since the antitumor effect may be the result of the fall in EGF receptors in cancers, information on the time course of changes in these receptors during treatment with these analogs may lead to an improvement in therapeutic regimens.
Tárgyszavak:	Orvostudományok Gyógyszerészeti tudományok idegen nyelvű folyóiratközlemény külföldi lapban külföldön készült közlemény
Megjelenés:	Journal of Cancer Research and Clinical Oncology. - 125 : 8-9 (1999), p. 444-452. -
További szerzők:	Halmos Gábor (1962-) (gyógyszerész, receptorfarmakológus, experimentális onkológus) Schally, Andrew Victor Arencibia, José M. Groot, Kate Vadillo-Buenfil, Manuel Rodriguez-Martin, Eulalia
Internet cím:	Szerző által megadott URL DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon: